[go: up one dir, main page]

TW200609216A - New aminopyridine derivatives and their use as pharmaceuticals - Google Patents

New aminopyridine derivatives and their use as pharmaceuticals

Info

Publication number
TW200609216A
TW200609216A TW094117274A TW94117274A TW200609216A TW 200609216 A TW200609216 A TW 200609216A TW 094117274 A TW094117274 A TW 094117274A TW 94117274 A TW94117274 A TW 94117274A TW 200609216 A TW200609216 A TW 200609216A
Authority
TW
Taiwan
Prior art keywords
disorders
sexual
disorder
compounds
sexual dysfunction
Prior art date
Application number
TW094117274A
Other languages
Chinese (zh)
Inventor
Charlotte Moira Norfor Allerton
Andrew Simon Cook
David Hepworth
Duncan Charles Miller
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200609216(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of TW200609216A publication Critical patent/TW200609216A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides for compounds of formula (I) which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.
TW094117274A 2004-05-27 2005-05-26 New aminopyridine derivatives and their use as pharmaceuticals TW200609216A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
TW200609216A true TW200609216A (en) 2006-03-16

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094117274A TW200609216A (en) 2004-05-27 2005-05-26 New aminopyridine derivatives and their use as pharmaceuticals

Country Status (21)

Country Link
EP (1) EP1758862A1 (en)
JP (1) JP4198183B2 (en)
AP (1) AP2006003824A0 (en)
AR (1) AR049548A1 (en)
AU (1) AU2005247699A1 (en)
BR (1) BRPI0511571A (en)
CA (1) CA2567935C (en)
EA (1) EA200601982A1 (en)
EC (1) ECSP067029A (en)
GT (1) GT200500125A (en)
IL (1) IL179314A0 (en)
MA (1) MA28607B1 (en)
MX (1) MXPA06013786A (en)
NL (1) NL1029139C2 (en)
NO (1) NO20065326L (en)
PA (1) PA8635101A1 (en)
PE (1) PE20060366A1 (en)
SV (1) SV2005002129A (en)
TW (1) TW200609216A (en)
UY (1) UY28925A1 (en)
WO (1) WO2005115985A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) * 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
KR20110114663A (en) 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 Fused Pyrimidine
MX357614B (en) * 2010-04-12 2018-07-17 Supernus Pharmaceuticals Inc Methods for producing viloxazine salts and novel polymorphs thereof.
KR101972618B1 (en) 2011-06-30 2019-08-16 도날드슨 컴파니, 인코포레이티드 Air/oil separator assemblies;components and methods
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
PT3971177T (en) 2016-07-20 2024-07-30 Novartis Ag Aminopyridine derivatives and their use as selective alk-2 inhibitors
SG11202005138TA (en) * 2017-12-08 2020-06-29 Boehringer Ingelheim Int Imidazopyridine derivatives and the use thereof as medicament
WO2020210785A1 (en) * 2019-04-12 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
WO2021102258A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
CN115968289B (en) 2020-06-16 2025-09-30 因赛特公司 ALK2 inhibitors for the treatment of anemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
OA13014A (en) * 2002-12-10 2006-11-10 Pfizer Morpholine derivatives for use as dopamine agonists in the treatment of i.a sexual dysfunction.

Also Published As

Publication number Publication date
EP1758862A1 (en) 2007-03-07
SV2005002129A (en) 2005-12-13
MXPA06013786A (en) 2007-01-25
NO20065326L (en) 2006-12-19
AU2005247699A1 (en) 2005-12-08
GT200500125A (en) 2006-01-10
NL1029139C2 (en) 2006-06-19
PE20060366A1 (en) 2006-05-15
AP2006003824A0 (en) 2006-12-31
BRPI0511571A (en) 2008-01-02
JP2008500331A (en) 2008-01-10
CA2567935C (en) 2009-10-27
IL179314A0 (en) 2007-03-08
AR049548A1 (en) 2006-08-16
ECSP067029A (en) 2006-12-29
PA8635101A1 (en) 2006-05-16
WO2005115985A1 (en) 2005-12-08
MA28607B1 (en) 2007-05-02
UY28925A1 (en) 2005-12-30
EA200601982A1 (en) 2007-04-27
NL1029139A1 (en) 2005-11-30
CA2567935A1 (en) 2005-12-08
JP4198183B2 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
AR113758A1 (en) PROCESS FOR THE PREPARATION OF 6- (2-HYDROXY-2-METHYLPROPOXY) -4- (6- (6 - ((6-METOXYPIRIDIN-3-IL) METHYL) -3,6-DIAZABICYCLO [3.1.1] HEPTAN- 3-IL) PYRIDIN-3-IL) PYRAZOLO [1,5-A] PYRIDINE-3-CARBONITRILE
TN2014000070A1 (en) Pyrimidine pde10 inhibitors
MX2015012502A (en) Dna-pk inhibitors.
HRP20150437T1 (en) DIARYLHYDANTOIN COMPOUNDS AS ANTAGONISTS OF ANDROGEN RECEPTOR FOR CANCER TREATMENT
CL2012003604A1 (en) Heterocyclic compounds derived from substituted pyridine carboxamide; Preparation process; pharmaceutical composition; pharmaceutical combination; use in the treatment of cell proliferative disorders, parkinson's disease, cancer, among others.
TW200609216A (en) New aminopyridine derivatives and their use as pharmaceuticals
MX2014000779A (en) Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands.
TW200505410A (en) Treatment of sexual dysfunction
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
UA116894C2 (en) Novel pyrazine derivatives as cb2 receptor agonists
PH12014501821A1 (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
JO2999B1 (en) Tricyclic Compound And Pharmaceutical Use Therof
TW200607500A (en) New indazole and indolone derivatives and their use as pharmaceuticals
EA201400423A1 (en) PHARMACEUTICAL PREPARATIONS AND THEIR APPLICATION IN THE TREATMENT OF SEXUAL DYSFUNCTION IN WOMEN
EA201590884A1 (en) METHODS OF TREATING LIVER DISEASES
MX2019014272A (en) Ergoline derivatives for use in medicine.
DOP2005000095A (en) NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS
TH75888A (en) New aminopyridine derivatives and their use as pharmaceuticals
PH12020550726B1 (en) Method and compositions for the treatment of diabetes and related symptoms
DOP2005000093A (en) NEW DERIVATIVES OF INDAZOL AND INDOLONA AND ITS USE AS PHARMACEUTICAL PRODUCTS
TH75891A (en) New indonesol and indolone derivatives And its use as a pharmacological substance
MA44836A (en) KIDNEY POLYCYSTIC SYNDROME TREATMENT METHODS
MX2012014968A (en) Fixed doses of a tadalafil and dapoxetine pharmaceutical combination.
GB2423029A (en) Penis erection-enhancing device and methods of use thereof